登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688321 证券简称：微芯生物 公告编号：2025-076 深圳微芯生物科技股份有限公司 股东博奥生物集团有限公司保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 股东持股的基本情况 本次减持计划实施前，深圳微芯生物科技股份有限公司(以下简称"公司")持股5%以上股东博奥生物集团 有限公司（以下简称"博奥生物"）持有公司股份34,705,162股，占公司总股本比例为8.51%。 ● 减持计划的主要内容和实施结果情况 公司于2025年9月11日披露了《关于持股5%以上股东减持股份计划的公告》（公告编号：2025-055）， 因战略规划有资金需求，博奥生物自公告披露之日起15个交易日后通过集中竞价交易与大宗交易相结合 的方式减持所持有的公司股份合计数量不超过12,233,893股（即不超过公司总股本的3%），采取集中竞 价交易方式的，在任意连续90日内，减持股份的总数不超过公司股份总数的1%，采取大宗交易方式 的，在任意连续90日内，减 ...

Core Viewpoint - The major shareholder of Microchip Biotech, Boao Biological Group, has completed a share reduction plan, selling 12.23 million shares, which is 3% of the company's total equity, for approximately 322 million yuan. This reduction will not significantly impact the company's governance structure or operations [2][7][8]. Group 1: Shareholder Actions - Boao Biological Group, the largest shareholder of Microchip Biotech, held 34.71 million shares (8.51% of total equity) before the reduction [7]. - The share reduction was initiated on September 11, 2025, due to strategic funding needs, with a plan to sell up to 12.23 million shares through a combination of centralized bidding and block trading [7][8]. - The reduction was executed between October 14 and November 26, 2025, with a total of 407.80 million shares sold through centralized bidding and 815.59 million shares through block trading, at prices ranging from 23.59 yuan to 31.10 yuan per share [8]. Group 2: Company Financing Plans - Microchip Biotech is advancing a plan to issue A-shares to specific investors, aiming to raise up to 950 million yuan for innovative drug research, the construction of a new drug manufacturing base, and to supplement working capital [9]. - The fundraising plan has been approved by the company's board and shareholders, pending approval from the Shanghai Stock Exchange and registration with the China Securities Regulatory Commission [9]. - The funds will be allocated as follows: 350 million yuan for innovative drug research, 350 million yuan for the first phase of the new drug manufacturing base, and 250 million yuan for working capital [11]. Group 3: Research and Development Focus - Microchip Biotech is focusing on multiple key Phase II and III clinical trials, including a Phase II study for a combination treatment for advanced pancreatic ductal adenocarcinoma and a Phase III study for a colorectal cancer indication [11][12]. - The company reported significant revenue growth for its products, with a 125.7% year-on-year increase for one drug in the first half of 2025 and an 18.8% increase for another in the same period [11][12].

Core Viewpoint - The major shareholder of Microchip Biotech, Boao Biological Group, has completed a share reduction plan, selling 12.23 million shares, which is 3% of the company's total shares, for approximately 322 million yuan. This reduction will not significantly impact the company's governance structure or operations [1][5][6]. Group 1: Shareholder Actions - Boao Biological Group, the largest shareholder of Microchip Biotech, has reduced its holdings from 8.51% to 5.51% after selling 12.23 million shares [6]. - The share reduction was executed between October 14 and November 26, 2025, with a total sale amount of 322 million yuan, and the share price ranged from 23.59 yuan to 31.10 yuan [6][5]. - The market reaction to the share reduction was minimal, with only a 0.32% decline in the stock price during the reduction period [6]. Group 2: Fundraising and Investment Plans - Microchip Biotech is advancing a plan to issue A-shares to specific investors, aiming to raise up to 950 million yuan for innovative drug research, the construction of a new drug manufacturing base, and to supplement working capital [7][8]. - The fundraising plan has been approved by the company's board and shareholders, pending regulatory approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [7]. - The allocation of the raised funds includes 350 million yuan for innovative drug research, 350 million yuan for the first phase of the new drug manufacturing base, and 250 million yuan for working capital [7][8]. Group 3: Drug Development Progress - Microchip Biotech is focusing on multiple key Phase II and III clinical trials, including a Phase II study for a combination treatment for advanced pancreatic cancer and a Phase III trial for a colorectal cancer treatment [8][9]. - The company reported significant revenue growth for its drugs, with a 125.7% increase for one drug in the first half of 2025 and an 18.8% increase for another in the same period [8][9].

Mergers and Acquisitions - Aladdin plans to acquire 35% equity of Youke for a cash consideration of 61.25 million yuan [1] - Huafeng Aluminum intends to acquire 100% equity of Huafeng Puen for a cash amount of 100 million yuan [2] Shareholding Changes - New锐股份 announces that its major shareholder plans to reduce its stake by up to 0.50%, equating to a maximum of 1.2622 million shares [3] - 微芯生物 reports that 博奥生物 has completed a share reduction of 3%, totaling 12.2339 million shares [4] - *ST宝实's controlling shareholder plans to increase its stake in the company, with an investment ranging from 21 million to 42 million yuan [5] Risk Matters - *ST广道's stock is set to be delisted following a decision from the exchange, with a potential review application period of 15 trading days [6] - 天下秀 announces a tax payment and penalty of approximately 24.5157 million yuan, which is expected to reduce its 2025 net profit by about 23.8413 million yuan, representing 46.30% of the latest audited net profit [7] - ST泉为's subsidiary is involved in a significant lawsuit with a claim amounting to 32.7616 million yuan, with uncertain impacts on future profits [8] Market Rumors - 实达集团 clarifies that rumors regarding a partnership with Alibaba Cloud are untrue, and the acquisition of a 95% stake in Fujian Shuchan Ming Shang Technology remains uncertain [9]

两融数据显示，该股最新融资余额为6.23亿元，近5日减少6118.73万元，降幅为8.94%。（数据宝） 11月26日微芯生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 105.02 | 2541.55 | 24.20 | -12.98 | 机构专用 | 国投证券股份有限公司深 | | | | | | | 圳宝安海秀路证券营业部 | | 50.00 | 1210.00 | 24.20 | -12.98 | 华宝证券股份有限公司合 | 国投证券股份有限公司深 | | | | | | 肥潜山路证券营业部 | 圳宝安海秀路证券营业部 | | 10.00 | 242.00 | 24.20 | -12.98 | 中国银河证券股份有限公 | 国投证券股份有限公司深 | | | | | | 司金华证券营业部 | 圳宝安海秀路证券营业部 | | 10.00 | 242.00 | 24 ...

证券日报网讯 11月26日晚间，微芯生物发布公告称，本次减持计划实施前，深圳微芯生物科技股份有 限公司（以下简称"公司"）持股5%以上股东博奥生物集团有限公司（以下简称"博奥生物"）持有公司 股份34，705，162股，占公司总股本比例为8.51%。2025年11月26日，公司收到股东博奥生物发来的 《关于权益变动触及1%刻度暨减持结果的告知函》。博奥生物于2025年10月14日至2025年11月26日期 间通过集中竞价、大宗交易方式合计减持公司股份12，233，893股，占公司股份总数的3%，本次减持 计划已实施完毕。2025年11月20日至2025年11月26日，博奥生物通过大宗交易方式合计减持公司股份 5，283，929股，与天府清源控股有限公司合计持有公司股份数量从35，969，608股减少至30，685， 679股，合计持有公司股份比例从本次权益变动前的8.82%减少至7.52%，权益变动触及1%刻度。 （文章来源：证券日报） ...

深圳微芯生物科技股份有限公司 关于 5%以上股东权益变动触及 1%刻度暨减持股份 结果公告 股东博奥生物集团有限公司保证向本公司提供的信息真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 证券代码：688321 证券简称：微芯生物 公告编号：2025-076 股东持股的基本情况 本次减持计划实施前，深圳微芯生物科技股份有限公司(以下简称"公司") 持股 5%以上股东博奥生物集团有限公司（以下简称"博奥生物"）持有公司股份 34,705,162 股，占公司总股本比例为 8.51%。 减持计划的主要内容和实施结果情况 公司于 2025 年 9 月 11 日披露了《关于持股 5%以上股东减持股份计划的公 告》（公告编号：2025-055），因战略规划有资金需求，博奥生物自公告披露之 日起 15 个交易日后通过集中竞价交易与大宗交易相结合的方式减持所持有的公 司股份合计数量不超过 12,233,893 股（即不超过公司总股本的 3%），采取集中 竞价交易方式的，在任意连续 90 日内，减持股份的总数不超过公司股份总数的 1%， ...

格隆汇11月26日丨微芯生物(688321.SH)公布，2025年11月26日，公司收到股东博奥生物发来的《关于 权益变动触及1%刻度暨减持结果的告知函》。博奥生物于2025年10月14日至2025年11月26日期间通过 集中竞价、大宗交易方式合计减持公司股份1223.39万股，占公司股份总数的3%，本次减持计划已实施 完毕。 ...

南财智讯11月26日电，微芯生物公告，公司收到股东博奥生物集团有限公司发来的《关于权益变动触及 1%刻度暨减持结果的告知函》。2025年10月14日至2025年11月26日，博奥生物通过集中竞价和大宗交 易方式合计减持公司股份12,233,893股，占公司总股本的3%，本次减持计划已实施完毕。本次权益变动 后，博奥生物及其一致行动人天府清源控股有限公司合计持有公司股份比例由8.82%减少至7.52%。本 次减持未导致公司控股股东、实际控制人发生变化，对公司治理结构及持续经营无重大影响。 ...

微芯生物公告，股东博奥生物完成减持计划，2025年10月14日至11月26日通过集中竞价减持407.8万 股、大宗交易减持815.59万股，合计1223.39万股，占总股本3%；减持后持股2247.13万股，占5.51%。 2025年11月20日至11月26日，博奥生物大宗交易减持528.39万股，其与一致行动人天府清源控股合计持 股比例由8.82%降至7.52%，触及1%刻度。 ...